nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Tizanidine—CYP1A2—chronic obstructive pulmonary disease	0.0103	0.501	CrCbGaD
Apraclonidine—Clonidine—CYP1A1—chronic obstructive pulmonary disease	0.0052	0.254	CrCbGaD
Apraclonidine—Clonidine—CYP1A2—chronic obstructive pulmonary disease	0.00501	0.245	CrCbGaD
Apraclonidine—Pharyngitis—Montelukast—chronic obstructive pulmonary disease	0.00272	0.00327	CcSEcCtD
Apraclonidine—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.00271	0.00325	CcSEcCtD
Apraclonidine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.0027	0.00324	CcSEcCtD
Apraclonidine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.0027	0.00324	CcSEcCtD
Apraclonidine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00268	0.00322	CcSEcCtD
Apraclonidine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.00267	0.00321	CcSEcCtD
Apraclonidine—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.00265	0.00318	CcSEcCtD
Apraclonidine—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.00264	0.00317	CcSEcCtD
Apraclonidine—Pharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.00262	0.00315	CcSEcCtD
Apraclonidine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00259	0.00312	CcSEcCtD
Apraclonidine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00259	0.00311	CcSEcCtD
Apraclonidine—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00257	0.00309	CcSEcCtD
Apraclonidine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.00257	0.00309	CcSEcCtD
Apraclonidine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00256	0.00308	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00255	0.00307	CcSEcCtD
Apraclonidine—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00252	0.00303	CcSEcCtD
Apraclonidine—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00252	0.00303	CcSEcCtD
Apraclonidine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00251	0.00302	CcSEcCtD
Apraclonidine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.0025	0.003	CcSEcCtD
Apraclonidine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.0025	0.003	CcSEcCtD
Apraclonidine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00249	0.00299	CcSEcCtD
Apraclonidine—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00247	0.00297	CcSEcCtD
Apraclonidine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00247	0.00296	CcSEcCtD
Apraclonidine—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00246	0.00296	CcSEcCtD
Apraclonidine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00245	0.00295	CcSEcCtD
Apraclonidine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00245	0.00295	CcSEcCtD
Apraclonidine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00245	0.00295	CcSEcCtD
Apraclonidine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00245	0.00294	CcSEcCtD
Apraclonidine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00242	0.0029	CcSEcCtD
Apraclonidine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.0024	0.00289	CcSEcCtD
Apraclonidine—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.0024	0.00288	CcSEcCtD
Apraclonidine—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00239	0.00288	CcSEcCtD
Apraclonidine—Tension—Formoterol—chronic obstructive pulmonary disease	0.00239	0.00287	CcSEcCtD
Apraclonidine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00239	0.00287	CcSEcCtD
Apraclonidine—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00238	0.00287	CcSEcCtD
Apraclonidine—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00238	0.00287	CcSEcCtD
Apraclonidine—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00238	0.00286	CcSEcCtD
Apraclonidine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.00237	0.00284	CcSEcCtD
Apraclonidine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.00237	0.00284	CcSEcCtD
Apraclonidine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00236	0.00284	CcSEcCtD
Apraclonidine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00236	0.00284	CcSEcCtD
Apraclonidine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00233	0.0028	CcSEcCtD
Apraclonidine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00231	0.00278	CcSEcCtD
Apraclonidine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00226	0.00272	CcSEcCtD
Apraclonidine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00226	0.00272	CcSEcCtD
Apraclonidine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00226	0.00271	CcSEcCtD
Apraclonidine—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.00225	0.00271	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00224	0.0027	CcSEcCtD
Apraclonidine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00223	0.00268	CcSEcCtD
Apraclonidine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00223	0.00268	CcSEcCtD
Apraclonidine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.00221	0.00266	CcSEcCtD
Apraclonidine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.0022	0.00264	CcSEcCtD
Apraclonidine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.0022	0.00264	CcSEcCtD
Apraclonidine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00215	0.00259	CcSEcCtD
Apraclonidine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00215	0.00259	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00214	0.00257	CcSEcCtD
Apraclonidine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00213	0.00256	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00213	0.00256	CcSEcCtD
Apraclonidine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00211	0.00253	CcSEcCtD
Apraclonidine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00211	0.00253	CcSEcCtD
Apraclonidine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Apraclonidine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Apraclonidine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Apraclonidine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Apraclonidine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00207	0.00249	CcSEcCtD
Apraclonidine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00206	0.00248	CcSEcCtD
Apraclonidine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00206	0.00248	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00206	0.00247	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00206	0.00247	CcSEcCtD
Apraclonidine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00205	0.00246	CcSEcCtD
Apraclonidine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00205	0.00246	CcSEcCtD
Apraclonidine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00203	0.00244	CcSEcCtD
Apraclonidine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00203	0.00244	CcSEcCtD
Apraclonidine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00203	0.00244	CcSEcCtD
Apraclonidine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00203	0.00244	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00202	0.00242	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00201	0.00242	CcSEcCtD
Apraclonidine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00199	0.00239	CcSEcCtD
Apraclonidine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00199	0.00239	CcSEcCtD
Apraclonidine—Infection—Formoterol—chronic obstructive pulmonary disease	0.00197	0.00237	CcSEcCtD
Apraclonidine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00197	0.00237	CcSEcCtD
Apraclonidine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00196	0.00235	CcSEcCtD
Apraclonidine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00196	0.00235	CcSEcCtD
Apraclonidine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00195	0.00234	CcSEcCtD
Apraclonidine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00195	0.00234	CcSEcCtD
Apraclonidine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00195	0.00234	CcSEcCtD
Apraclonidine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00195	0.00234	CcSEcCtD
Apraclonidine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00193	0.00232	CcSEcCtD
Apraclonidine—Infection—Montelukast—chronic obstructive pulmonary disease	0.00193	0.00232	CcSEcCtD
Apraclonidine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00193	0.00232	CcSEcCtD
Apraclonidine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00193	0.00232	CcSEcCtD
Apraclonidine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00192	0.00231	CcSEcCtD
Apraclonidine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00191	0.0023	CcSEcCtD
Apraclonidine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00191	0.00229	CcSEcCtD
Apraclonidine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00189	0.00227	CcSEcCtD
Apraclonidine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00188	0.00226	CcSEcCtD
Apraclonidine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00186	0.00224	CcSEcCtD
Apraclonidine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00185	0.00222	CcSEcCtD
Apraclonidine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00184	0.00221	CcSEcCtD
Apraclonidine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00182	0.00219	CcSEcCtD
Apraclonidine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00181	0.00218	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00181	0.00218	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00181	0.00218	CcSEcCtD
Apraclonidine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.0018	0.00216	CcSEcCtD
Apraclonidine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.0018	0.00216	CcSEcCtD
Apraclonidine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00179	0.00215	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00177	0.00213	CcSEcCtD
Apraclonidine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00177	0.00213	CcSEcCtD
Apraclonidine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00177	0.00213	CcSEcCtD
Apraclonidine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00177	0.00212	CcSEcCtD
Apraclonidine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00177	0.00212	CcSEcCtD
Apraclonidine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00176	0.00212	CcSEcCtD
Apraclonidine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00175	0.0021	CcSEcCtD
Apraclonidine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00174	0.00209	CcSEcCtD
Apraclonidine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00173	0.00208	CcSEcCtD
Apraclonidine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00173	0.00208	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00172	0.00206	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00172	0.00206	CcSEcCtD
Apraclonidine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00171	0.00206	CcSEcCtD
Apraclonidine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00171	0.00206	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00171	0.00206	CcSEcCtD
Apraclonidine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.0017	0.00204	CcSEcCtD
Apraclonidine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.0017	0.00204	CcSEcCtD
Apraclonidine—Pain—Formoterol—chronic obstructive pulmonary disease	0.0017	0.00204	CcSEcCtD
Apraclonidine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.0017	0.00204	CcSEcCtD
Apraclonidine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.0017	0.00204	CcSEcCtD
Apraclonidine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00169	0.00203	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00168	0.00202	CcSEcCtD
Apraclonidine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00168	0.00202	CcSEcCtD
Apraclonidine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00167	0.00201	CcSEcCtD
Apraclonidine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00167	0.00201	CcSEcCtD
Apraclonidine—Pain—Montelukast—chronic obstructive pulmonary disease	0.00166	0.002	CcSEcCtD
Apraclonidine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00166	0.002	CcSEcCtD
Apraclonidine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.00198	CcSEcCtD
Apraclonidine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00164	0.00197	CcSEcCtD
Apraclonidine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00164	0.00197	CcSEcCtD
Apraclonidine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00164	0.00197	CcSEcCtD
Apraclonidine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00164	0.00197	CcSEcCtD
Apraclonidine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00163	0.00196	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00163	0.00195	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00163	0.00195	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00162	0.00195	CcSEcCtD
Apraclonidine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00162	0.00194	CcSEcCtD
Apraclonidine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.0016	0.00193	CcSEcCtD
Apraclonidine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.0016	0.00193	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00159	0.00191	CcSEcCtD
Apraclonidine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00157	0.00189	CcSEcCtD
Apraclonidine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00157	0.00189	CcSEcCtD
Apraclonidine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00157	0.00188	CcSEcCtD
Apraclonidine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00155	0.00186	CcSEcCtD
Apraclonidine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00155	0.00186	CcSEcCtD
Apraclonidine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.00186	CcSEcCtD
Apraclonidine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00154	0.00185	CcSEcCtD
Apraclonidine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00154	0.00185	CcSEcCtD
Apraclonidine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00154	0.00185	CcSEcCtD
Apraclonidine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.00154	0.00185	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00153	0.00184	CcSEcCtD
Apraclonidine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00152	0.00183	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.00152	0.00182	CcSEcCtD
Apraclonidine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00148	0.00178	CcSEcCtD
Apraclonidine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00146	0.00176	CcSEcCtD
Apraclonidine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00146	0.00176	CcSEcCtD
Apraclonidine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00146	0.00176	CcSEcCtD
Apraclonidine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00146	0.00175	CcSEcCtD
Apraclonidine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00143	0.00172	CcSEcCtD
Apraclonidine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00143	0.00171	CcSEcCtD
Apraclonidine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00143	0.00171	CcSEcCtD
Apraclonidine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00141	0.00169	CcSEcCtD
Apraclonidine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00141	0.00169	CcSEcCtD
Apraclonidine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.0014	0.00168	CcSEcCtD
Apraclonidine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00138	0.00166	CcSEcCtD
Apraclonidine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00138	0.00166	CcSEcCtD
Apraclonidine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00136	0.00163	CcSEcCtD
Apraclonidine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00136	0.00163	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00135	0.00163	CcSEcCtD
Apraclonidine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00135	0.00162	CcSEcCtD
Apraclonidine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00133	0.0016	CcSEcCtD
Apraclonidine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.0016	CcSEcCtD
Apraclonidine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00132	0.00159	CcSEcCtD
Apraclonidine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00131	0.00158	CcSEcCtD
Apraclonidine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00131	0.00158	CcSEcCtD
Apraclonidine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00129	0.00155	CcSEcCtD
Apraclonidine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00128	0.00154	CcSEcCtD
Apraclonidine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00126	0.00152	CcSEcCtD
Apraclonidine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00126	0.00152	CcSEcCtD
Apraclonidine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00125	0.0015	CcSEcCtD
Apraclonidine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.0015	CcSEcCtD
Apraclonidine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.0015	CcSEcCtD
Apraclonidine—Headache—Formoterol—chronic obstructive pulmonary disease	0.00125	0.0015	CcSEcCtD
Apraclonidine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00124	0.00149	CcSEcCtD
Apraclonidine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.00149	CcSEcCtD
Apraclonidine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00124	0.00149	CcSEcCtD
Apraclonidine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00147	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00122	0.00147	CcSEcCtD
Apraclonidine—Headache—Montelukast—chronic obstructive pulmonary disease	0.00122	0.00147	CcSEcCtD
Apraclonidine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00143	CcSEcCtD
Apraclonidine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00119	0.00143	CcSEcCtD
Apraclonidine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00118	0.00142	CcSEcCtD
Apraclonidine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00142	CcSEcCtD
Apraclonidine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00118	0.00142	CcSEcCtD
Apraclonidine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00118	0.00142	CcSEcCtD
Apraclonidine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00141	CcSEcCtD
Apraclonidine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00139	CcSEcCtD
Apraclonidine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.00112	0.00135	CcSEcCtD
Apraclonidine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00134	CcSEcCtD
Apraclonidine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.00111	0.00133	CcSEcCtD
Apraclonidine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.0011	0.00132	CcSEcCtD
Apraclonidine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00108	0.00129	CcSEcCtD
Apraclonidine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.00103	0.00124	CcSEcCtD
Apraclonidine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000999	0.0012	CcSEcCtD
Apraclonidine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000984	0.00118	CcSEcCtD
Apraclonidine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000974	0.00117	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000967	0.00116	CcSEcCtD
Apraclonidine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000965	0.00116	CcSEcCtD
Apraclonidine—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000958	0.00115	CcSEcCtD
Apraclonidine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00092	0.00111	CcSEcCtD
Apraclonidine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000903	0.00109	CcSEcCtD
Apraclonidine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000889	0.00107	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000887	0.00107	CcSEcCtD
Apraclonidine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000864	0.00104	CcSEcCtD
Apraclonidine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000859	0.00103	CcSEcCtD
Apraclonidine—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000816	0.000981	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00081	0.000974	CcSEcCtD
Apraclonidine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000806	0.000969	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000793	0.000953	CcSEcCtD
Apraclonidine—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000782	0.00094	CcSEcCtD
Apraclonidine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000777	0.000934	CcSEcCtD
Apraclonidine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000767	0.000922	CcSEcCtD
Apraclonidine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00076	0.000913	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000713	0.000857	CcSEcCtD
Apraclonidine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000712	0.000856	CcSEcCtD
Apraclonidine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000707	0.00085	CcSEcCtD
Apraclonidine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000702	0.000844	CcSEcCtD
Apraclonidine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000678	0.000815	CcSEcCtD
Apraclonidine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000674	0.000811	CcSEcCtD
Apraclonidine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000674	0.00081	CcSEcCtD
Apraclonidine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000669	0.000804	CcSEcCtD
Apraclonidine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000645	0.000775	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00064	0.000769	CcSEcCtD
Apraclonidine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000639	0.000768	CcSEcCtD
Apraclonidine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000618	0.000743	CcSEcCtD
Apraclonidine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000576	0.000693	CcSEcCtD
Apraclonidine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000561	0.000674	CcSEcCtD
Apraclonidine—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000553	0.000665	CcSEcCtD
Apraclonidine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000535	0.000643	CcSEcCtD
Apraclonidine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000517	0.000622	CcSEcCtD
Apraclonidine—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000497	0.000598	CcSEcCtD
Apraclonidine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000493	0.000592	CcSEcCtD
Apraclonidine—Headache—Prednisone—chronic obstructive pulmonary disease	0.00049	0.000589	CcSEcCtD
Apraclonidine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000465	0.000558	CcSEcCtD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000359	0.00244	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000359	0.00244	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.00035	0.00237	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000346	0.00235	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000345	0.00234	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000339	0.0023	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000336	0.00227	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APIP—chronic obstructive pulmonary disease	0.000335	0.00227	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000331	0.00225	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00033	0.00223	CbGpPWpGaD
Apraclonidine—ADRA1A—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000329	0.00223	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000323	0.00219	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000322	0.00218	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000317	0.00215	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	0.000314	0.00213	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000314	0.00213	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000309	0.0021	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000308	0.00209	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000306	0.00208	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	0.000306	0.00207	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	0.000305	0.00207	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000302	0.00205	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000301	0.00204	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000296	0.00201	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000296	0.00201	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000293	0.00199	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.00029	0.00197	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000289	0.00196	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	0.000286	0.00194	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	0.000285	0.00193	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000282	0.00191	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000281	0.00191	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000278	0.00189	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000276	0.00187	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000275	0.00187	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000273	0.00185	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	0.000273	0.00185	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.000271	0.00184	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GC—chronic obstructive pulmonary disease	0.000266	0.0018	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000262	0.00178	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.00026	0.00176	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000259	0.00176	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000258	0.00175	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000256	0.00174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000253	0.00171	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000252	0.00171	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000247	0.00167	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000247	0.00167	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000245	0.00166	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	0.000244	0.00166	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000242	0.00164	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000241	0.00163	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000238	0.00161	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000236	0.0016	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000235	0.00159	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	0.000232	0.00157	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	0.000232	0.00157	CbGpPWpGaD
Apraclonidine—ADRA2C—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.00023	0.00156	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000228	0.00155	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000227	0.00154	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000226	0.00153	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000226	0.00153	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000222	0.0015	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	0.00022	0.00149	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	0.000216	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000211	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	0.00021	0.00143	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.00021	0.00142	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000208	0.00141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000206	0.0014	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000204	0.00138	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000201	0.00136	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.0002	0.00135	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000197	0.00134	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	0.000196	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000196	0.00133	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000194	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	0.000193	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000192	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.00019	0.00129	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000187	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000187	0.00127	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000186	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000185	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000183	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000183	0.00124	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	0.00018	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000175	0.00119	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000175	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000173	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000163	0.00111	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.00016	0.00109	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	0.00016	0.00108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000159	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000158	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000158	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	0.000158	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000157	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000156	0.00106	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	0.000155	0.00105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000151	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.00015	0.00102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000149	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000149	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000149	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000148	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.000147	0.000998	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000147	0.000996	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	0.000146	0.000993	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000146	0.000989	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000145	0.000984	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000143	0.000973	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000143	0.000967	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	0.000142	0.000963	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000142	0.000961	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000141	0.000953	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000141	0.000953	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.00014	0.000946	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000139	0.000945	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000137	0.000926	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000133	0.000898	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000132	0.000898	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000131	0.000888	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.00013	0.000878	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000128	0.000865	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000127	0.000864	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000124	0.000841	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000122	0.000827	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000122	0.000826	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000121	0.000823	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.000818	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.00012	0.000816	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	0.00012	0.000811	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	0.000119	0.000809	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000118	0.000803	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000118	0.000799	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000117	0.00079	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000116	0.000785	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000116	0.000785	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	0.000114	0.000774	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000113	0.000768	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000113	0.000768	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000112	0.000756	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000109	0.00074	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—VEGFA—chronic obstructive pulmonary disease	0.000108	0.000735	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000108	0.000729	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000106	0.000721	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000104	0.000702	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000102	0.000692	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000102	0.000688	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—VEGFA—chronic obstructive pulmonary disease	0.000101	0.000687	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000101	0.000686	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000101	0.000682	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.95e-05	0.000675	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.92e-05	0.000673	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.8e-05	0.000664	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.48e-05	0.000643	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.41e-05	0.000638	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.37e-05	0.000635	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.3e-05	0.00063	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.25e-05	0.000627	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.92e-05	0.000605	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.77e-05	0.000594	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.75e-05	0.000593	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	8.44e-05	0.000572	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.37e-05	0.000568	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.29e-05	0.000562	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.29e-05	0.000562	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	8.23e-05	0.000558	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—chronic obstructive pulmonary disease	8.19e-05	0.000555	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.17e-05	0.000554	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.06e-05	0.000546	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.88e-05	0.000534	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.82e-05	0.00053	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.7e-05	0.000522	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.66e-05	0.000519	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—chronic obstructive pulmonary disease	7.65e-05	0.000519	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.65e-05	0.000519	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.61e-05	0.000516	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	7.55e-05	0.000512	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.51e-05	0.000509	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.33e-05	0.000497	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.16e-05	0.000485	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.12e-05	0.000483	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.11e-05	0.000482	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.11e-05	0.000482	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.89e-05	0.000467	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.84e-05	0.000464	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.84e-05	0.000464	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.81e-05	0.000462	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.4e-05	0.000434	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.36e-05	0.000431	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.35e-05	0.000431	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.26e-05	0.000424	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	6.22e-05	0.000421	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.22e-05	0.000421	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.98e-05	0.000406	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	5.96e-05	0.000404	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.81e-05	0.000394	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.77e-05	0.000391	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	5.7e-05	0.000386	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.6e-05	0.00038	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.56e-05	0.000377	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.56e-05	0.000377	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.34e-05	0.000362	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.23e-05	0.000355	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.17e-05	0.00035	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.1e-05	0.000346	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.99e-05	0.000338	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	4.84e-05	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.77e-05	0.000323	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	4.63e-05	0.000314	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.57e-05	0.00031	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.53e-05	0.000307	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.36e-05	0.000296	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.3e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.25e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.23e-05	0.000287	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.17e-05	0.000282	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.09e-05	0.000278	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.05e-05	0.000275	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.02e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.87e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.82e-05	0.000259	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.7e-05	0.000251	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.68e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.51e-05	0.000238	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.43e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.43e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.37e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.34e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.31e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.27e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.15e-05	0.000214	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.11e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.09e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.79e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.78e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.75e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.7e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.59e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.56e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.54e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.51e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.37e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.27e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.11e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.08e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.93e-05	0.000131	CbGpPWpGaD
